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Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of liver disease in the United
States and is associated with an increased risk of cardiovascular disease (CVD) and cardiovascular
(CV) mortality, independent of traditional cardiovascular risk factors. CVD is one of the most
common causes of death among individuals with NAFLD and management of NAFLD must
extend beyond liver disease to include CVD risk modification. Clinicians should assess CVD risk
with the Framingham Risk Score (FRS) and screen for CVD risk factors including dyslipidemia,
diabetes mellitus (DM), hypertension, tobacco use and the metabolic syndrome (MetS). CVD risk
factors, particularly dyslipidemia, require aggressive medical management to reduce the high risk
of CVD events and death in individuals with NAFLD.
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Background
NAFLD impacts 30–40% of Americans.1 Nonalcoholic steatohepatitis (NASH), the
progressive form of NAFLD, impacts 2–12% of Americans.2 NASH can lead to the
development of cirrhosis and it is predicted that by 2020, NASH cirrhosis will be the leading
indication for liver transplantation in the United States.3
While NASH can result in end stage liver disease, steatosis and NASH are associated with
an increased risk of CVD events and death both independently and by their frequent
association with the MetS, insulin resistance and dyslipidemia.4 A meta-analysis assessing
the natural history of NAFD found that while NASH was associated with increased liver-
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related mortality when compared to steatosis, there was no difference in the risk of CVD-
related death between NASH and steatosis.4 Currently, CVD is the leading cause of death in
individuals with NAFLD.5 Modification of CVD risk factors, particularly dyslipidemia, is
necessary to decrease CVD morbidity and mortality in individuals with NAFLD. In this
review, we will address the need for CVD risk stratification and outline methods for CVD
risk management in individuals with NAFLD. While the breadth of data on CVD risk
management in NAFLD is expanding, limitations remain. Where data are unavailable for
NAFLD specifically, we have drawn from the CVD literature in the general population and
in individuals with other CVD risk factors.
Dyslipidemia in NAFLD
Dyslipidemia is frequent in individuals with NAFLD. A substudy from the Multi-Ethnic
Study of Atherosclerosis (MEAS) assessed the relationship between radiographically
diagnosed NAFLD and dyslipidemia.6 NAFLD was independently associated with elevated
triglyceride levels, increased low-density lipoprotein (LDL) particle concentration,
decreased LDL particle size and decreased high-density lipoprotein (HDL) levels after
controlling for insulin resistance. These findings have been replicated in individuals with
NAFLD from other community cohorts and in individuals with NAFLD and DM.7, 8 In
addition, non-HDL-cholesterol (non-HDL-C) is increased in individuals with NASH.9 Non-
HDL-C is a measure of all atherogenic lipoproteins including very-low density lipoproteins
(VLDL), LDL, intermediate-density lipoproteins (IDL) and Lipoprotein a (Lp(a)).10 Non-
HDL-C is calculated from a standard lipid panel (Non-HDL-C= Total cholesterol–HDL) and
guidelines cite non-HDL-C<150mg/dL as a secondary target for lipid lowering therapy.11, 12
Cardiovascular Disease and NAFLD
CVD events are a frequent cause of morbidity and mortality in individuals with NAFLD.
(Table 1) Three community-based studies have demonstrated that individuals with
radiographically diagnosed NAFLD have an increased risk of CVD events and mortality
compared to individuals without NAFLD.13–15 Hamaguchi et al. assessed 1637 subjects in a
community-based cohort from Japan for NAFLD by ultrasonography.16 Nineteen percent of
the cohort was found to have NAFLD. Cardiovascular events occurred in 5.2% of NAFLD
subjects and 1.0% of non-NAFLD individuals over 5 years. (p<0.01) This difference
remained statistically significant after adjustment for the MetS. Adams et al. found a high
incidence of CV mortality in a US-based cohort.14 Four hundred twenty individuals with
NAFLD were followed for a median of 7.6 years. Individuals with NAFLD had significantly
increased mortality when compared to the general population with a standardized mortality
ratio of 1.34 (95% CI: 1.003–1.76). Targher et al. found that CVD events and mortality were
also more common among diabetic individuals with NAFLD than diabetics without NAFLD
[OR: 1.87 (95% CI: 1.2–2.60)].13
Histologically defined NAFLD is also associated with an increased CVD risk. Soderberg et
al. performed liver biopsies in 256 subjects, 118 of whom had NAFLD which were blindly
scored for steatosis and NASH.17 Individuals with NAFLD (both steatosis and NASH) had a
69% increased mortality compared with the overall population. Ekstedt et al. also found that
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individuals with NASH had increased mortality compared to the general population, a
difference not seen in those with only steatosis.18 Again, CVD was the most common cause
of death among individuals with NASH. Thus, individuals with both radiographically and
histologically defined NAFLD are at increased risk for CVD and mortality.
Cardiovascular Risk Stratification in NAFLD
Several different methods are used in the general population to estimate CVD risk including
the Framingham Risk Score (FRS). The FRS is a validated measure of cardiovascular risk in
the general population. Incorporating age, gender, cholesterol, HDL, smoking status and
hypertension, the FRS predicts an individual’s 10-year risk of myocardial infarction or CVD
death. Further, the FRS has been validated as a predictor of CVD in NAFLD and should be
used to risk stratify individuals and guide treatment of risk factors including dyslipidemia.19
The MetS is frequent in individuals with NAFLD and associated with increased CVD and
all-cause mortality.20, 21 Therefore, assessment for the MetS is an important component of
CVD risk stratification. Several definitions for MetS exist.22 The MetS as defined by the
National Cholesterol Education Program (NCEP) requires the presence three or more of the
following components:
1. Elevated triglycerides (≥150mg/dL)
2. Low HDL (<40mg/dl in men, <50mg/dl in women)
3. Elevated fasting glucose (≥110mg/dL)
4. Hypertension (≥130/85 mm Hg or on anti-hypertensive medication)
5. Abdominal obesity (waist circumference >102cm in men, >88cm in women)
In addition to evaluation for the MetS, individuals should be evaluated for other CVD risk
factors including DM which can be diagnosed using fasting glucose or glycosylated
hemoglobin (HbA1C).23
Cardiac stress testing, carotid artery intima-media thickness (CIMT) assessment and
coronary artery calcium (CAC) score can also add in CVD risk stratification. These
modalities can be used to detect subclinical atherosclerotic disease and to predict future CV
events.23–25 Individuals with NAFLD and elevated CVD risk have been found to have
increased mean CIMT levels and elevated CAC scores suggesting the utility of these tests
for risk stratification in individuals with NAFLD.26–28
Management of Dyslipidemia and Cardiovascular Disease Risk in NAFLD
Lifestyle modification, encompassing weight loss and increased physical activity, is the
cornerstone of dyslipidemia management in NAFLD. However, for groups with elevated
CVD risk, lifestyle modification should be accompanied by lipid lowering therapy.
Guidelines set forth by the NCEP Adult Treatment Panel III provide guidance on which
groups should be targeted for lipid lowering therapy and outline treatment goals. (Figure
1)12 These guidelines were not specifically designed to address dyslipidemia in individuals
with NAFLD. However, they can be safely applied to individuals with NAFLD.
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Dietary Modification
Little data are available for the preferred diet for individuals with NAFLD. Two small
studies have suggested that diets low in carbohydrates may result in a reduction in
intrahepatic triglyceride concentration and an improvement in histologically defined
NAFLD.29, 30 Low carbohydrate diets have a beneficial effect on serum lipid levels.31 For
LDL lowering, the NCEP recommends a diet low in saturated fat (<7% of total calories) and
cholesterol (<200mg/day). Plant sterols and stanols as well as increased intake of soluble
fiber can also be used for dietary lipid lowering.12
Recently, a large randomized controlled trial found that subjects who consumed a
Mediterranean diet had a reduction in the incidence of cardiac events compared to those
receiving only advice on low fat diets.32 Limited data exist on the benefit of the
Mediterranean diet in NAFLD. A trial of 12 subjects with biopsy-proven NAFLD assessed
the impact of a Mediterranean diet on hepatic steatosis as assessed by magnetic resonance
spectroscopy (MRS).33 Subjects undertook, in random order, 6 weeks of a low fat, high
carbohydrate diet and a Mediterranean diet, separated by a 6 week wash out period. MRS
steatosis decreased significantly in the group receiving the Mediterranean diet compared to
the low fat, high carbohydrate diet (39% reduction vs. 7% reduction, p=0.012), with no
difference in weight loss between groups. This study suggests that in individuals with
NAFLD the Mediterranean diet may have benefits beyond the management of dyslipidemia.
However, further studies are needed before this diet can be routinely recommended.
Fructose consumption, present in processed foods and beverages, is associated with NAFLD
development.34 The impact of fructose avoidance has yet to be rigorously evaluated but
individuals should be advised to limit fructose consumption. The United States Dietary
Guidelines for 2010 classifies fructose as an “added sugar” and recommends limiting added
sugars to ≤3 or less servings per day for persons on <2,000 calorie per day diets and ≤5
servings per day for those on ≥2,000 calorie diets.
Exercise
Regular exercise is associated with decreased triglycerides and LDL and increased HDL
levels.35, 36 The NCEP recommends at least 30 minutes of moderate activity most days of
the week as part of dyslipidemia management.12 Exercise is independently associated with a
reduction in aminotransferase levels and hepatic triglyceride content. Sixty minutes per
week of aerobic exercise decreases aminotransferase levels in subjects with NAFLD.37 A
trial of subjects with NAFLD randomized to no exercise or three 30–45 minute cycling
sessions weekly found that the cycling group had a significant decrease in hepatic
triglyceride content and visceral adipose content without a change in overall body weight.38
Individuals with NAFLD should be advised to participate in regular, aerobic exercise.
Cigarette Smoking and Alcohol Use
Cigarette smoking is associated with increased CVD and all-cause mortality. The American
College of Cardiology recommends that individuals who use tobacco receive counseling
regarding smoking cessation and, if needed, referral to tobacco cessation support
programs.23 Moderate alcohol intake, defined as one unit of alcohol daily for women and 2
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units daily for men, may increase HDL and apolipoprotein AI levels and decreased risk.12
Therefore, moderate alcohol use maybe helpful in reducing CVD risk.
Several studies have suggested that mild to moderate alcohol use may be protective against
NAFLD development.39, 40 However, no data exist to determine the impact of alcohol use
on existing NAFLD or NASH or on the impact of alcohol use on CVD risk in individuals
with NAFLD. Therefore, it is premature to recommend regular alcohol use in individuals
with NAFLD.
Obstructive Sleep Apnea (OSA)
OSA is characterized by periods of apnea during sleep resulting in oxygen desaturation.
Chronically, OSA increases the risk of the MetS, CVD and sudden death while treatment of
OSA improves the MetS and decreases CVD mortality.41–4445, 46
Several studies suggest a relationship between OSA and NAFLD. Animal models have
demonstrated that mice exposed to chronic intermittent hypoxia are more likely to develop
steatosis and hepatic inflammation.47, 48 In humans, several studies have demonstrated a
relationship between OSA and NAFLD. A study of subjects with OSA and NASH found
that the oxygen desaturation index, a measure of OSA severity, was directly correlated with
NASH activity score and fibrosis stage even after adjustment for insulin resistance and
obesity.49 Additionally, a prospective study of individuals with radiographically defined
NAFLD and OSA found that the initiation of continuous positive airway pressure (CPAP)
lead to an improvement in radiographic steatosis.50 Thus, a potential link between NAFLD
and OSA may exist and requires further evaluation. It would be premature to suggest that
OSA treatment will improve NAFLD. However, because treatment of OSA does improve
the MetS and CVD risk, screening for OSA should be considered in individuals with
NAFLD.
Diabetes Mellitus (DM)
DM is associated with an increased risk of CVD. As DM is highly prevalent among
individuals with NAFLD, comprehensive management is essential for CVD risk reduction.
A detailed discussion of the management of DM in individuals with NAFLD is beyond the
scope of this review. However, primary and secondary prevention of CVD events in
individuals with DM should focus on multifactorial risk reduction, including treatment of
hypertension and dyslipidemia.51 In addition, specific treatments of DM including
metformin may decrease CVD events.52.
Lipid Lowering Medications
HMG-CoA Reductase Inhibitors
Treatment of dyslipidemia should not be withheld in individuals with NAFLD. HMG-CoA
reductase inhibitors or “statins” have a well established role in the primary and secondary
prevention of CVD and individuals with NAFLD can benefit from risk reduction.12 A post-
hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE)
study demonstrated not only that statins are safe in individuals with abnormal liver function
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tests presumably due to NAFLD but that individuals with NAFLD who received statins had
a significant reduction in cardiovascular events when compared to those with NAFLD not
on statins (10% vs. 30%, p<0.0001).53 Thus, statins significantly reduce cardiovascular
events in individuals with NAFLD and should be used for individuals who require lipid
lowering therapy.
Early data suggest that statins may also have a specific role in the treatment of NAFLD
although this requires confirmation before it can be widely applied.54 A retrospective trial of
statin use in 68 individuals with histologically defined NAFLD found that those who used
statins had a reduction in steatosis, despite a higher mean BMI and prevalence of DM, than
those not on statins.55 In addition, the rate of fibrosis development was unexpectedly low in
individuals on statin therapy. In individuals with radiographically defined NAFLD,
atorvastatin has been shown in several studies to be associated with NAFLD
regression.54, 56, 57 However, a randomized controlled trial of simvastatin in NASH therapy
did not result in any histologic benefit.58 Thus, the impact of statin therapy on NAFLD
remains uncertain. Importantly, however, statin hepatotoxicity was not reported in any
study, reinforcing that statins are safe in individuals with NAFLD.
In addition to the role of statins in management of dyslipidemia, statins may also play a role
in the prevention of hepatocellular carcinoma (HCC).59 Using a community-based cohort of
individuals with DM, a nested case-control study found that a significantly fewer cases
(individuals with HCC) were prescribed statins when compared to controls, suggesting a
preventive role for statins in HCC development. While this study was not designed to assess
HCC prevention in those with NAFLD, its finding may be applicable to those with NAFLD.
Statin hepatotoxicity
Concern for hepatotoxicity associated with statins has led to reluctance on the part of
clinicians to treat dyslipidemia in individuals with NALFD.60 However, the incidence of
statin-induced hepatotoxicity in those with NAFLD is vanishingly low and not greater than
that experienced in the general population.61–64 Chalasani et al. evaluated the incidence of
aminotransferase elevations in individuals with baseline elevations in aminotransferases
(presumably secondary to NAFLD) on statins, and individuals with elevated liver enzymes
who did not receive statins64 When compared to those with elevated liver enzymes not
receiving statins, individuals with elevated baseline liver enzymes on statins did not have a
higher incidence of either mild-moderate elevations (4.7% vs. 6.4%, P = 0.2) or severe
elevations (0.6% vs. 0.4%, P = 0.6). These findings have been replicated in a randomized
controlled trial of high dose pravastatin in individuals with chronic liver disease,
predominantly from NAFLD.65
Omega-3 Fatty Acids
If additional lipid lowering therapy is needed beyond statins, omega-3 fatty acids can be
safely given in individuals with NAFLD. Omega-3 fatty acids reduce serum triglycerides by
reducing VLDL secretion from hepatocytes. Omega-3 fatty acids in doses of 3–4 grams
daily are associated with a decrease in triglycerides (−25–35%) and a small increase in HDL
levels (1–3%).66, 67 Early studies suggest that omega-3 fatty acids may improve
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aminotransferase levels and radiographic steatosis in individuals with NAFLD and
dyslipidemia and thus, are attractive for dyslipidemia management in individuals with
NASH.68–70
Fibrates
Fibrates act to lower serum triglycerides while simultaneously increasing HDL. While
fibrates reduce cardiovascular mortality among individuals with elevated triglycerides they
do not decrease cardiovascular mortality among individuals with normal triglyceride levels.
Statins carry a risk of muscle toxicity. When statins are taken in combination with fibrates
the risk is increased. This risk can be reduced by using hydrophilic statins (i.e. pravastatin,
rosuvasatin, fluvastatin and atorvastatin) which have less muscle penetration than
hydrophilic statins, when combination therapy with fibrates is needed.71, 72
Fenofibrate has been studied in individuals with NAFLD.73 In a trial of 16 individuals with
biopsy-proven NAFLD, fenofibrate 200mg daily for 48 weeks decreased triglyceride,
glucose, gamma-glutamyl transpeptidase and alkaline phosphatase levels. In addition, a
decrease in hepatocyte ballooning was seen. However, there was no significant change in
steatosis grade, NASH activity score, lobular inflammation or fibrosis. However, a second
trial of using clofibrate did not demonstrate a change in aminotransferase levels or
histology.74 No hepatotoxicity was reported from fibrates in any of the above trials.
Therefore, while fibrates have not been shown to consistently improve NAFLD
histologically, they do offer an effective treatment for hypertriglyceridemia and can be used
safely in individuals with NAFLD.
Niacin
Niacin (nicotinic acid) lowers lipids by inhibiting the hepatic production of lipoproteins.
Niacin lowers triglyceride levels and is associated with reduced cardiovascular mortality.75
However, niacin should be used with caution in DM as it can worsen glucose intolerance. As
glucose intolerance may be associated with the development and progression of NAFLD, it
should not be first line therapy for hypertriglyceridemia.
Lipid Treatment Goals
LDL targets designed to reduce CVD risk have been established by the National Cholesterol
Education Program Adult Treatment Panel III (NCEP-ATP III). These guidelines provide
individualized LDL goals based on the assessment of an individual’s CVD risk factors
(Figure 1).
Fatty Liver and Newly Approved Lipid Lowering Agents
Statins are effective LDL lowering agents; however, in an important subset of individuals,
statins cannot lower LDL to goal treatment levels. Therefore, the search for medications to
improve LDL lowering is ongoing. Two new lipid lowering agents have recently been
approved. Mipomersen, an anti-sense oligonucleotide binds to and degrades hepatic apoB
mRNA, decreasing circulating LDL levels. Mipomersen is effective at LDL lowering in
individuals with hyperlipidemia, homozygous familial hypercholesterolemia (HFH) and
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statin intolerance.76–78 However, 11–33% of subjects receiving mipomersen developed
elevations in aminotransferase levels >3 times the upper limit of normal (ULN). Of the 14
individuals who developed elevations in aminotransferase levels, steatosis assessed by MRS
was found in 12. Two of these individuals underwent liver biopsy. Both patients were found
to have NASH, one without fibrosis and one with stage 1 fibrosis. These findings suggest an
association between mipomersen use and fatty liver.
A second mechanism for lipoprotein reduction is through microsomal triglyceride
transferase protein (MTTP) inhibition. MTTP catalyzes the formation of apoB containing
proteins in the liver. Lomitapide, an MTTP inhibitor, has been shown in individuals with
hypercholesterolemia and HFH to lower LDL levels. However, like mipomersen, lomitapide
is associated with frequent elevations in aminotransferase levels and radiographic
steatosis.79, 80 As a result, lomitapide is approved for HFH but comes with a black box
warning for hepatotoxicity. Thus, while mipomersen and lomitapide are beneficial in
lowering LDL levels, they are associated with hepatotoxicity, possible NASH development
and cannot currently be recommended for lipid lowering therapy in individuals with
NAFLD.
Future Directions
NAFLD is a rising epidemic in the United States and is associated with cardiovascular
mortality. Many individuals with NAFLD will die from CVD prior to the development of
end stage liver disease. Thus, the careful management of CVD risk factors including
dyslipidemia in individuals with NAFLD is essential to reduce CVD-related mortality.
Gastroenterologists and hepatologists should play an active role in comprehensive CVD risk
assessment including screening for dyslipidemia, DM, the MetS, cigarette smoking and
alcohol use. Management of CVD risk factors should be grounded in counseling of lifestyle
modification including weight loss, dietary changes and increased physical activity. When
needed, this should be accompanied by lipid lowering medication with treatment goals set
by the NCEP. Comprehensive evaluation and aggressive management of CVD risk factors in
individuals with NAFLD could significantly decrease CVD events and deaths.
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Figure 1.
Cardiovascular Risk Assessment in NAFLD
*Adapted from the National Cholesterol Education Program ATP III Guidelines
NAFLD: non-alcoholic fatty liver disease, HbA1C: glycosylated hemoglobin, CVD:
cardiovascular disease, LDL: low density lipoprotein, FH family history, HDL: high density
lipoprotein
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